Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 35-39

  Honkoop, A H ^a   Hoekman, K ^a   Wagstaff, J ^a   Boven, E ^a   Van Groeningen, C J ^a   Giaccone, G ^a   Vermerken, J B ^a   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Chemotherapy; Dose Intensity; GM CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTOPENIA;

EID: 0030032778     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010474     Document Type: Article

References (25)

1. Hryniuk W, Bush H. The importance of intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1988; 2: 1281-515.
2. Antman KH. Dose-intensive chemotherapy in breast cancer. In Antman KH, Armitage O (eds): High Dose Chemotherapy. Baltimore MD: Williams & Wilkins 1992; 701-18.
3. Honkoop AH, Pinedo HM. High-dose chemotherapy in the treatment of breast cancer. Int J Oncol 1995; 6: 911-8.
4. Frei E, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-94.
5. Carmo-Pereira J, Oliveira Costa F, Henriques E et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471-3.
6. Bronchud MH, Howell A, Crowther D et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121-5.
7. Jones RB, Holland JF, Bhardwaj S et al. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172-7.
8. Frei E III, Teicher BA, Holden SA et al. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-23.
9. Hoekman K, Wagstaff J, van Groeningen CJ et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991; 83: 1546-53.
10. Weisbart RH, Gasson JC, Golde DW. Colony-stimulating factors and host defense. Ann Int Med 1989; 110: 297-303.
11. Vantongelen K (ed). A Practical Guide to EORTC Studies 1994. Brussels: EORTC Central Office-Data Center 1994.
12. Fountzilas G, Skarlos D, Giannakakis T et al. Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. Eur J Cancer 1994; 7: 965-9.
13. Ferguson JE, Dodwell DJ, Seymour A-M et al. High-dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 1993; 67: 825-9.
14. Ardizzoni A, Venturini M, Sertoli MR et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 1994; 69: 385-91.
15. O'Shaughnessy JA, Denicoff AM, Venzon DJ et al. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coliderived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncol 1994; 5: 709-16.
16. Focan C, Andrien JM, Closon MTh et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 1993; 11: 1253-63.
17. Skipper EH. Dose intensity versus total dose of chemotherapy: An experimental basis. In De Vita Jr, VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott 1990; 43-64.
18. Skipper HE. Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res 1967; 27: 2636-45.
19. Simpson-Herren L, Lloyd HH. Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother Rep 1970; 54: 143-79.
20. Suderland M, Abeloff M, Neidhart J. Continuous GM-CSF failed to ameliorate neutropenia and worsened thrombocytopenia in a dose-intensive regimen for breast cancer. Breast Cancer Res Treat 1991; 19: 158 (Abstr).
21. Rodriquez M, Swan F, Hagemeister F et al. High-dose ESHAP with GM-CSF vs. prophylactic antibiotics. Blood 1990; 76 (Suppl): 370A.
22. Antman KS, Griffin JD, Elias A et al. Effect of recombinant granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593-8.
23. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
24. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992; 19: 317-32.
25. Peters WP, Shpall EJ, Jones RB et al. High-dose combination Cyclophosphamide (CPA), Cisplatin (CDDP), and Carmustine (BCNU) with bone marrow support as initial tratment for metastatic breast cancer: Three-six-year follow-up. Proc Am Soc Clin Oncol 1992; 9: 10 (Abstr).